Di Liu is a Partner at Cowin Venture. Prior to joining Cowin in 2015, she had been director at GSR Ventures and application support consultant at Roche Diagnostics. Di has led the investments in Gateway Medical, Paragon Genomics, Sensulin, NeuCyte, Taproot, Geneus-tech, Changjiang Biotechnology, and Mirabilis Medica etc. Di Liu holds an MS in Biology from University of Pennsylvania and a BS in Biology from Tsinghua University.